BI-847325 - CAS 1207293-36-4
Catalog number: B0084-470824
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Aurora Kinase | MEK
BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-470824 10 mg $169 In stock
Bulk Inquiry
Solid Powder
BI-847325; BI 847325; BI847325.
DMSO: 19mg/mL warmed(40.89mM); Ethanol: 1mg/mL(2.15mM); Water: <1mg/mL(<1mM)
3 years -20℃ powder; 6 months -80℃ in solvent
Shelf Life:
2 years
Canonical SMILES:
1.The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
Phadke MS;Sini P;Smalley KS Mol Cancer Ther. 2015 Jun;14(6):1354-64. doi: 10.1158/1535-7163.MCT-14-0832. Epub 2015 Apr 14.
Resistance to BRAF inhibitors is a major clinical problem. Here, we evaluate BI-847325, an ATP-competitive inhibitor of MEK and Aurora kinases, in treatment-naïve and drug-resistant BRAF-mutant melanoma models. BI-847325 potently inhibited growth and survival of melanoma cell lines that were both BRAF inhibitor naïve and resistant in 2D culture, 3D cell culture conditions, and in colony formation assays. Western blot studies showed BI-847325 to reduce expression of phospho-ERK and phospho-histone 3 in multiple models of vemurafenib resistance. Mechanistically, BI-847325 decreased the expression of MEK and Mcl-1 while increasing the expression of the proapoptotic protein BIM. Strong suppression of MEK expression was observed after 48 hours of treatment, with no recovery following >72 hours of washout. siRNA-mediated knockdown of Mcl-1 enhanced the effects of BI-847325, whereas Mcl-1 overexpression reversed this in both 2D cell culture and 3D spheroid melanoma models. In vivo, once weekly BI-847325 (70 mg/kg) led to durable regression of BRAF-inhibitor naïve xenografts with no regrowth seen (>65 days of treatment). In contrast, treatment with the vemurafenib analog PLX4720 was associated with tumor relapse at >30 days.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Aurora Kinase Products

CAS 1094067-13-6 SCH1473759 (HCl salt)

SCH1473759 (HCl salt)
(CAS: 1094067-13-6)

The hydrochloride salt form of SCH-1473759, a new sub-nanomolar Aurora A/B inhibitor which could result in cell death by inhibiting Aurora kinases. It is proved...

CAS 923032-37-5 Refametinib

(CAS: 923032-37-5)

Refametinib, also known as RDEA119, BAY 86-9766, is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor RDEA119...

CAS 946128-88-7 RO5126766

(CAS: 946128-88-7)

RO5126766, also known as CH5126766, is a protein kinase inhibitor specific for the Raf and MEK mitogen-activated protein kinases (MAPKs) with potential anti-ne...

CAS 656820-32-5 Reversine

(CAS: 656820-32-5)

Reversine is a small molecule developed by the group of Peter G. Schultz, used for stem cell dedifferentiation. Reversine is also a novel Aurora kinases inhibit...

CAS 391210-00-7 PD318088

(CAS: 391210-00-7)

PD318088 is a MEK inhibitor

(CAS: 765958-29-0)

SMK-17 is a MEK1/2 inhibitor. It can inhibit MEK1 kinase activity in a non-ATP-competitive manner and it is highly selective to MEK1 and 2. SMK-17 can inhibit t...

CAS 874101-00-5 RO4987655

(CAS: 874101-00-5)

RO4987655 is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK ...

CAS 1146618-41-8 SNS-314 Mesylate

SNS-314 Mesylate
(CAS: 1146618-41-8)

SNS-314 Mesylate is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. It is less potent to T...

Chemical Structure

CAS 1207293-36-4 BI-847325

Quick Inquiry

Verification code

Featured Items